Cardiovascular Risk Reduction With GLP-1 RA Drugs
Listen to this summary
This paper reviews the cardiovascular risk reduction associated with GLP-1 receptor agonists (RAs), originally developed for type 2 diabetes management. The authors aim to elucidate how these agents not only improve glycemic control but also confer significant cardiovascular benefits, including reductions in major adverse events across various populations. Additionally, the paper discusses the potential of emerging therapies that target multiple incretin pathways to further enhance these cardiovascular outcomes.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Circulation
View all →Jul 9, 2026 · Circulation
Exercise Training in High-Risk Populations: A Scientific Statement From the American Heart Association
Jul 8, 2026 · Circulation
Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association
Jun 29, 2026 · Circulation
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
Jun 26, 2026 · Circulation
Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry
Jun 24, 2026 · Circulation
Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association
Jun 22, 2026 · Circulation
Challenges and Future Trends in Large Vessel Vasculitis
More in Thoracic Surgery (Cardiothoracic Vascular Surgery)
View all →Jul 10, 2026 · Lancet (London, England)
Advancing the relevance of clinical trials for older patients
Jul 9, 2026 · Lancet (London, England)
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial
Jul 9, 2026 · JAMA
Formulary-Related Insurance Denials of Single-Source Branded Drugs in the United States
Jul 9, 2026 · Lancet (London, England)
Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations
Jul 9, 2026 · Lancet (London, England)
Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial
Jul 8, 2026 · The New England journal of medicine
Meningococcal B Vaccine to Prevent <em>Neisseria gonorrhoeae</em> Infection
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
